VNDA (Vanda Pharmaceuticals) Total Stockholders Equity : $541.2 Mil (As of Sep. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Total Stockholders Equity?

Vanda Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $541.2 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Vanda Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 was $9.28. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Vanda Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.01.

Vanda Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Vanda Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals Total Stockholders Equity Chart

Vanda Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

410.95

453.27

504.93

527.20

544.91

Vanda Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															543.10	544.91	544.00	542.52	541.22

Vanda Pharmaceuticals (NAS:VNDA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Vanda Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(541.223	-	0)	/	58.3061
	=	9.28

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Vanda Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.454	+	5.486)	/	541.223
	=	0.01

Vanda Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vanda Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

0LKB:UK VM4:Germany VM4:Germany

Address

2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037

Website

https://www.vandapharma.com

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Executives

Stephen Ray Mitchell	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran	officer: VP, Acting CFO & Treasurer	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams	officer: SVP & General Counsel	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Joakim Wijkstrom	officer: SVP, Chief Marketing Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Mihael Hristos Polymeropoulos	director, officer: Chief Executive Officer	9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks	officer: SVP, Business Development	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins	director	1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones	officer: Chief Corp. Affairs Officer	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos	director	2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan	director	20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly	officer: SVP, CFO, Treasurer & Secretar	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi	officer: SVP, General Manager Europe	2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward	director	C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341